Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Century Therapeutics Inc’s stock clocked out at $0.53, up 2.68% from its previous closing price of $0.51. In other words, the price has increased by $2.68 from its previous closing price. On the day, 0.97 million shares were traded. IPSC stock price reached its highest trading level at $0.5405 during the session, while it also had its lowest trading level at $0.51.
Ratios:
To gain a deeper understanding of IPSC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.25 and its Current Ratio is at 6.25. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In the most recent recommendation for this company, Rodman & Renshaw on August 08, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On August 28, 2023, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $28 to $5.
On December 27, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $19.Chardan Capital Markets initiated its Buy rating on December 27, 2022, with a $19 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 20 ’25 when Cowan Chad sold 5,462 shares for $0.50 per share. The transaction valued at 2,736 led to the insider holds 987,027 shares of the business.
Pfeiffenberger Brent bought 35,000 shares of IPSC for $17,328 on Nov 19 ’25. The President and CEO now owns 3,271,453 shares after completing the transaction at $0.50 per share. On Nov 20 ’25, another insider, Cowan Chad, who serves as the Officer of the company, bought 5,462 shares for $0.50 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IPSC now has a Market Capitalization of 45957712 and an Enterprise Value of -41885932. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.41 while its Price-to-Book (P/B) ratio in mrq is 0.26. Its current Enterprise Value per Revenue stands at -0.37 whereas that against EBITDA is 4.273.
Stock Price History:
The Beta on a monthly basis for IPSC is 1.81, which has changed by -0.6631579 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, IPSC has reached a high of $1.74, while it has fallen to a 52-week low of $0.34. The 50-Day Moving Average of the stock is -3.06%, while the 200-Day Moving Average is calculated to be -4.46%.
Shares Statistics:
It appears that IPSC traded 954.81K shares on average per day over the past three months and 822130 shares per day over the past ten days. A total of 86.53M shares are outstanding, with a floating share count of 45.42M. Insiders hold about 47.98% of the company’s shares, while institutions hold 22.79% stake in the company. Shares short for IPSC as of 1763078400 were 497543 with a Short Ratio of 0.52, compared to 1760486400 on 349010. Therefore, it implies a Short% of Shares Outstanding of 497543 and a Short% of Float of 0.84.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 1.0 analysts currently analyzing and rating the stock of Century Therapeutics Inc (IPSC).The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.2 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$0.13 and -$0.27 for the fiscal current year, implying an average EPS of -$0.2. EPS for the following year is -$1.23, with 2.0 analysts recommending between -$0.9 and -$1.56.
Revenue Estimates
A total of 3 analysts have provided revenue estimates for IPSC’s current fiscal year. The highest revenue estimate was $109.16M, while the lowest revenue estimate was $109.16M, resulting in an average revenue estimate of $109.16M. In the same quarter a year ago, actual revenue was $6.59M
